Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genistein for the Reduction of Adverse Cardiovascular Events (GRACE)
NCT07785388Phase 2Not yet recruiting
- Start
- Sep 2026
- Primary completion
- Mar 2028
- Countries
- 1
01
Overview
A Phase 2 trial of genistein in human immunodeficiency virus infection (HIV), vascular disease, inflammation, pain. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
genistein
03
Conditions
human immunodeficiency virus infection (HIV)vascular diseaseinflammationpain
Beyond the preview
Go deeper on NCT07785388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07785388.